MCT1 and NHE1 expression is higher at the leading edge of tumors in GBM patients and in a rat glioma model; in contrast, MCT4 is upregulated in the perinecrotic tumor center, along with HIF1α, LDH, and CA9 [226,227,228]. This evidence concerns the gene SLC16A1 and glioblastoma.